e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Pulmonary circulation: clinical PAH, registries and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy
R. Cartin-Ceba, K. Swanson, M. Krowka (Rochester, United States Of America)
Source:
Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Session:
Pulmonary circulation: clinical PAH, registries and treatments
Session type:
Thematic Poster Session
Number:
949
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Cartin-Ceba, K. Swanson, M. Krowka (Rochester, United States Of America). Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy. Eur Respir J 2012; 40: Suppl. 56, 949
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy and safety of tadalafil in portopulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
Source: Eur Respir J 2013; 41: 96-103
Year: 2013
Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Efficacy and safety of bosentan in portopulmonary hypertension according to the severity of liver disease
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 651s
Year: 2006
Long-term outcome of patients with portopulmonary hypertension treated with sildenafil
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012
Iloprost treatment in portopulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Source: Eur Respir J 2007; 30: 1096-1102
Year: 2007
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension
Source: Eur Respir J, 53 (1) 1801880; 10.1183/13993003.01880-2018
Year: 2019
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: 563-567
Year: 2006
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005
Efficacy of oral add-on therapy in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data.
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept